{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T23:48:00Z","timestamp":1776296880259,"version":"3.50.1"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100008871","name":"Yunnan Provincial Science and Technology Department","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018531","name":"Major Science and Technology Projects in Yunnan Province","doi-asserted-by":"publisher","award":["202001AS070026"],"award-info":[{"award-number":["202001AS070026"]}],"id":[{"id":"10.13039\/501100018531","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.bmcl.2025.130423","type":"journal-article","created":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T01:17:57Z","timestamp":1759540677000},"page":"130423","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Discovery of novel VEGFR-2 inhibitors through virtual screening, synthesis and bioactivity evaluation"],"prefix":"10.1016","volume":"130","author":[{"given":"Xi","family":"Gu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linquan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianquan","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhili","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6801","key":"10.1016\/j.bmcl.2025.130423_bb0005","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/35025215","article-title":"Vascular-specific growth factors and blood vessel formation","volume":"407","author":"Yancopoulos","year":"2000","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.bmcl.2025.130423_bb0010","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1038\/nrc3627","article-title":"VEGF targets the tumour cell","volume":"13","author":"Goel","year":"2013","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"10.1016\/j.bmcl.2025.130423_bb0015","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ygyno.2012.06.038","article-title":"Cyclin I correlates with VEGFR-2 and cell proliferation in human epithelial ovarian cancer","volume":"127","author":"Cybulski","year":"2012","journal-title":"Gynecol Oncol"},{"issue":"4","key":"10.1016\/j.bmcl.2025.130423_bb0020","doi-asserted-by":"crossref","first-page":"E528","DOI":"10.1210\/jc.2011-1987","article-title":"CLM94, a novel cyclic amide with anti-VEGFR-2 and antiangiogenic properties, is active against primary anaplastic thyroid Cancer in vitro and in vivo","volume":"97","author":"Antonelli","year":"2012","journal-title":"J Clinical Endocrinol & Metabol"},{"issue":"4","key":"10.1016\/j.bmcl.2025.130423_bb0025","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1093\/neuonc\/nou234","article-title":"Effective treatment of diverse medulloblastoma models with mebendazole and its impact on tumor angiogenesis","volume":"17","author":"Bai","year":"2015","journal-title":"Neuro-Oncology."},{"key":"10.1016\/j.bmcl.2025.130423_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2024.122563","article-title":"VEGF\/VEGFR axis and its signaling in melanoma: current knowledge toward therapeutic targeting agents and future perspectives","volume":"345","author":"Malekan","year":"2024","journal-title":"Life Sci"},{"issue":"4","key":"10.1016\/j.bmcl.2025.130423_bb0035","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.prp.2018.02.005","article-title":"VEGFR-2 as a novel predictor of survival in gastric cancer: a systematic review and meta-analysis","volume":"214","author":"Li","year":"2018","journal-title":"Pathol Res Pract"},{"issue":"7","key":"10.1016\/j.bmcl.2025.130423_bb0040","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1007\/s40265-018-0903-9","article-title":"Apatinib: a review in advanced gastric Cancer and other advanced cancers","volume":"78","author":"Scott","year":"2018","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.bmcl.2025.130423_bb0045","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/ijc.23131","article-title":"E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition","volume":"122","author":"Matsui","year":"2007","journal-title":"Int J Cancer"},{"issue":"5","key":"10.1016\/j.bmcl.2025.130423_bb0050","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1158\/1078-0432.CCR-05-2028","article-title":"YM-359445, an orally bioavailable vascular endothelial growth factor Receptor-2 tyrosine kinase inhibitor, has highly potent antitumor activity against established tumors","volume":"12","author":"Amino","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.bmcl.2025.130423_bb0055","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.3390\/ijms19041232","article-title":"Resistance to anti-Angiogenic therapy in Cancer\u2014alterations to anti-VEGF pathway","volume":"19","author":"Itatani","year":"2018","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10.1016\/j.bmcl.2025.130423_bb0060","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1358\/dot.2013.49.5.1960218","article-title":"Tivozanib: Practical Implications for Renal Cell Carcinoma and Other Solid Tumors","volume":"Vol. 49","author":"Berge","year":"2013","journal-title":"Drugs of Today (Barcelona, Spain\u202f: 1998)"},{"issue":"16","key":"10.1016\/j.bmcl.2025.130423_bb0065","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1007\/s40265-018-0998-z","article-title":"Fruquintinib: first global approval","volume":"78","author":"Shirley","year":"2018","journal-title":"Drugs"},{"issue":"7","key":"10.1016\/j.bmcl.2025.130423_bb0070","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/nchembio799","article-title":"Rational design of inhibitors that bind to inactive kinase conformations","volume":"2","author":"Liu","year":"2006","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.bmcl.2025.130423_bb0075","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1146\/annurev-pharmtox-011112-140341","article-title":"Tyrosine kinase inhibitors: views of selectivity, sensitivity, and clinical performance","volume":"53","author":"Levitzki","year":"2013","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.bmcl.2025.130423_bb0080","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.phrs.2015.10.021","article-title":"Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes","volume":"103","author":"Roskoski","year":"2016","journal-title":"Pharmacol Res"},{"issue":"4","key":"10.1016\/j.bmcl.2025.130423_bb0085","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s11684-016-0488-1","article-title":"Mechanisms of resistance to third-generation EGFR tyrosine kinase inhibitors","volume":"10","author":"Wang","year":"2016","journal-title":"Front Med"},{"issue":"1","key":"10.1016\/j.bmcl.2025.130423_bb0090","doi-asserted-by":"crossref","first-page":"175","DOI":"10.7150\/ijbs.86305","article-title":"Mechanisms underlying therapeutic resistance of tyrosine kinase inhibitors in chronic myeloid leukemia","volume":"20","author":"Sun","year":"2024","journal-title":"Int J Biol Sci"},{"issue":"suppl_1","key":"10.1016\/j.bmcl.2025.130423_bb0095","first-page":"i10","article-title":"Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors. Annals of oncology\u202f: official journal of the European society for","volume":"29","author":"Westover","year":"2018","journal-title":"Med Oncol"},{"issue":"11","key":"10.1016\/j.bmcl.2025.130423_bb0100","doi-asserted-by":"crossref","first-page":"5420","DOI":"10.1016\/j.ejmech.2010.09.002","article-title":"Pharmacophore modeling and virtual screening studies for new VEGFR-2 kinase inhibitors","volume":"45","author":"Lee","year":"2010","journal-title":"Eur J Med Chem"},{"issue":"6","key":"10.1016\/j.bmcl.2025.130423_bb0105","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.jmgm.2008.11.008","article-title":"Pharmacophore modeling studies of type I and type II kinase inhibitors of Tie2","volume":"27","author":"Xie","year":"2009","journal-title":"J Mol Graph Model"},{"issue":"2","key":"10.1016\/j.bmcl.2025.130423_bb0110","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.bmcl.2008.11.056","article-title":"Pyridyl-pyrimidine benzimidazole derivatives as potent, selective, and orally bioavailable inhibitors of Tie-2 kinase","volume":"19","author":"Cee","year":"2009","journal-title":"Bioorg Med Chem Lett"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X25003324?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X25003324?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T08:16:02Z","timestamp":1761639362000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X25003324"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":22,"alternative-id":["S0960894X25003324"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2025.130423","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of novel VEGFR-2 inhibitors through virtual screening, synthesis and bioactivity evaluation","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2025.130423","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"130423"}}